Xencor (NASDAQ:XNCR) Shares Down 8% – Should You Sell?

Xencor, Inc. (NASDAQ:XNCR) was down 8% on Tuesday . The company traded as low as $12.01 and last traded at $12.0550. Approximately 533,193 shares changed hands during mid-day trading, a decline of 31% from the average daily volume of 773,562 shares. The stock had previously closed at $13.10.

Analyst Ratings Changes

Several equities analysts have recently issued reports on XNCR shares. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $13.00 price objective (down from $18.00) on shares of Xencor in a research note on Tuesday, March 24th. Weiss Ratings reissued a “sell (d-)” rating on shares of Xencor in a research note on Friday, March 27th. Wall Street Zen upgraded shares of Xencor from a “sell” rating to a “hold” rating in a report on Saturday, April 18th. Finally, Barclays lifted their price target on shares of Xencor from $26.00 to $27.00 and gave the stock an “overweight” rating in a research report on Thursday, February 26th. Six investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $24.38.

Xencor Stock Performance

The stock has a market capitalization of $891.08 million, a price-to-earnings ratio of -9.80 and a beta of 0.99. The stock’s 50-day simple moving average is $12.19 and its 200 day simple moving average is $13.67. The company has a quick ratio of 6.25, a current ratio of 6.25 and a debt-to-equity ratio of 0.12.

Xencor (NASDAQ:XNCR) last announced its earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.64) by $0.55. The business had revenue of $28.24 million for the quarter, compared to the consensus estimate of $29.97 million. Xencor had a negative return on equity of 14.58% and a negative net margin of 73.20%.Xencor’s revenue was down 46.6% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.62) EPS. Analysts expect that Xencor, Inc. will post -2.87 earnings per share for the current fiscal year.

Insider Transactions at Xencor

In other Xencor news, CEO Bassil I. Dahiyat sold 6,606 shares of the stock in a transaction dated Friday, March 6th. The shares were sold at an average price of $11.02, for a total transaction of $72,798.12. Following the sale, the chief executive officer owned 546,316 shares of the company’s stock, valued at $6,020,402.32. This represents a 1.19% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Celia Eckert sold 3,244 shares of the firm’s stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $11.25, for a total transaction of $36,495.00. Following the completion of the sale, the senior vice president owned 78,685 shares of the company’s stock, valued at $885,206.25. The trade was a 3.96% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 44,020 shares of company stock worth $499,817. Insiders own 5.23% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of XNCR. Inspire Investing LLC boosted its position in Xencor by 38.6% in the 1st quarter. Inspire Investing LLC now owns 42,529 shares of the biopharmaceutical company’s stock valued at $513,000 after buying an additional 11,853 shares during the last quarter. Louisiana State Employees Retirement System acquired a new position in shares of Xencor during the first quarter valued at $382,000. OP Asset Management Ltd bought a new position in Xencor in the first quarter valued at about $664,000. Diversified Trust Co boosted its holdings in Xencor by 16.7% in the first quarter. Diversified Trust Co now owns 21,528 shares of the biopharmaceutical company’s stock valued at $260,000 after acquiring an additional 3,086 shares during the last quarter. Finally, Seven Fleet Capital Management LP acquired a new stake in Xencor in the fourth quarter worth about $1,677,000.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.